Liqomics

As a liquid biopsy company, LIQOMICS is transforming oncology with non-invasive ctDNA analysis for cancer monitoring and treatment optimization. Our circulating tumor DNA (ctDNA) tests provide: Ultra-sensitive detection of minimal residual disease (MRD) Real-time insights into tumor genetics from a simple blood draw Exceptional precision for tracking treatment response We empower the hematology and oncology ecosystem to make data-driven decisions for lymphomas, solid tumors, and other malignancies by eliminating the need for invasive biopsies. Discover how our liquid biopsy technology is redefining cancer management.